Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Limited-Duration Teclistamab for the Treatment of Multiple Myeloma

Trial Status: active

This phase II trial compares the effect of continuing teclistamab to limited duration teclistamab in controlling multiple myeloma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Teclistamab is Food and Drug Administration (FDA)-approved as a continuous therapy for multiple myeloma. This means the drug is continued until it stops working (disease progression) to control multiple myeloma or until significant side-effects or complications develop. The information gain from this trial may help researchers learn if stopping teclistamab in multiple myeloma patients who have achieved a good response after completing 6-9 months of therapy works as well as continuing teclistamab until disease progression.